DXC to Exit Russia - Matching Employee Donations at 200%
DXC Technology condemns the unwarranted aggression from the Russian Government that is leading to the death, injury, and displacement of innocent civilians in Ukraine. DXC stands with every person, company, and government across the world that is calling for an immediate end to this unprovoked attack on Ukraine.
Currently, our number one priority is to care for our colleagues in the region. Our dedicated DXC team is working around the clock to provide shelter, financial assistance, health care, and relocation support to our colleagues and their families.
Based on the aggression from the Russian Government, we are no longer pursuing business in Russia and have committed to exit this market. We have approximately 4,000 colleagues in Russia and are supporting them in this time of need. We continue to support and maintain rigorous compliance with all applicable sanctions levied against Russia.
Aligned with our “People-first” strategy, DXC is matching employee donations to the Red Cross humanitarian efforts at 200% which includes providing direct financial support to our impacted colleagues. We are caring for all our people regardless of their nationality or country of origin.
We will continue to assess the situation and take the required measures leveraging the strength of our global team to help minimize any impact on our DXC colleagues and customers.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220304005261/en/
Contact information
Media
Sean B. Pasternak
Corporate Media Relations
1-647-975-7326
Sean.Pasternak@DXC.com
John Sweeney, CFA
Vice President, Investor Relations
+1-980-315-3665
John.Sweeney@DXC.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
iFIT Expands Global Reach with Rollout of AI Coach in 19 Countries2.6.2025 16:00:00 EEST | Press release
iFIT Inc., a global leader in connected fitness and interactive content, today announced the expansion of its iFIT AI Coach (beta) across 19 countries: Australia, Austria, Belgium, Canada, Finland, France, Germany, Ireland, Italy, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and the UK. This strategic expansion brings iFIT’s intelligent, personalized fitness technology to more athletes around the globe. AI Coach is iFIT’s most advanced digital training tool to date, leveraging proprietary technology and user data to deliver hyper-personalized fitness and wellness plans. The tool adapts dynamically to users' goals, schedules, and performance, offering real-time feedback and motivation across a wide range of fitness categories—from strength and cardio to recovery and mindfulness. “Expanding iFIT AI Coach beyond the U.S. reflects our mission to make intelligent, interactive fitness more accessible around the globe,” said Bart Mueller, Chief I
12BET Makes the Shortlist at the 2025 EGR Marketing & Innovation Awards2.6.2025 15:16:00 EEST | Press release
12BET, a pioneering name in the igaming world since 2007, is honored to be shortlisted in two categories at the 2025 EGR Marketing & Innovation Awards: Sportsbook Marketing Campaign, and Marketing Team of the Year – B2C. This recognition highlights the brand’s ongoing dedication to creating meaningful and original experiences that resonate with sports audiences and digital communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250519535436/en/ The EGR Marketing & Innovation Awards are among the most respected accolades in the online gaming industry. Held annually, the awards celebrate creativity, strategic thinking, and innovation across the sector, attracting participation from many of the world’s leading companies. For 12BET, being named a finalist is a meaningful milestone that showcases the brand’s energy, originality, and deep-rooted passion for sports culture. 12BET’s approach to creativity is rooted in connection
Adtran expands Oscilloquartz atomic clock portfolio with lower-cost optical cesium solutions for wider market adoption2.6.2025 15:00:00 EEST | Press release
Adtran today launched the latest additions to its Oscilloquartz optical cesium portfolio, expanding access to precision timing across a wider range of network environments. The new OSA 3200 SP and OSA 3250 ePRC leverage advanced optical pumping technology, offering improved holdover, simplified maintenance and a typical lifetime of 10 years. Built on the same proven platform as Adtran’s high-end cesium models, the solutions enable telecom operators, data centers, power utilities and defense networks to modernize synchronization infrastructure while lowering operational complexity and cost. The new models also address industry demand for alternatives to legacy magnetic cesium clocks that are more difficult to manage over time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530192819/en/ Adtran’s OSA 3200 SP and OSA 3250 ePRC will bring lower-cost optical pumping cesium technology to new markets and applications. “We develo
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 14:00:00 EEST | Press release
Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expertise across its diverse learner and corporate partner network. Massie continued, “With a network of over 30 manufacturing sites across nine
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 14:00:00 EEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom